Novacea, Inc. - Price Analysis Snapshot

This Report features up to a ten-year record of the equity Price history for Novacea, Inc.. Tabular results include the High, Low and Closing price for the quarter. There is also a calculation of percentage change in price for both Quarterly and Annual periods. Price values are adjusted for stock splits and dividends.

Novacea, Inc.. The Group's principal activity is that of a biopharmaceutical company focused on in-licensing, developing and commercializing novel therapies for the treatment of cancer. Its product portfolio features three clinical-stage oncology product candidates: DN-101, vinorelbine oral and AQ4N. Its lead product candidate, DN-101, is in a Phase 3 clinical trial for the treatment of androgen-independent prostate cancer. AQ4N is expected to advance into a Phase 1/2 clinical trial in the second half of 2006 for glioblastoma multiforme in combination with radiation and chemotherapy. It also seeks to develop anti-cancer agents that may reduce the toxicities associated with current treatments. Trademarks include Asentar and We Can. In May 2007, the Group signed an exclusive License, Development and Commercialization Agreement with Schering Corporation for the development and commercialization of 'Asentar.'

Not the Report you are looking for? Click here for more browsing options.

view sample Single Report

view sample All Basic Reports

Layout and Content of a Typical Report